Types of placenta accreta
|Classification and external resources|
Placenta accreta occurs when all or part of the placenta attaches abnormally to the myometrium (the muscular layer of the uterine wall). Three grades of abnormal placental attachment are defined according to the depth of invasion:
- Accreta – chorionic villi attach to the myometrium, rather than being restricted within the decidua basalis.
- Increta – chorionic villi invade into the myometrium.
- Percreta – chorionic villi invade through the myometrium.
Because of abnormal attachment to the myometrium, placenta accreta is associated with an increased risk of heavy bleeding at the time of attempted placental delivery. The need for transfusion of blood products is frequent, and hysterectomy is sometimes required to control life-threatening hemorrhage.
An important risk factor for placenta accreta is placenta previa in the presence of a uterine scar. Placenta previa is an independent risk factor for placenta accreta. Additional reported risk factors for placenta accreta include maternal age and multiparity, other prior uterine surgery, prior uterine curettage, uterine irradiation, endometrial ablation, Asherman syndrome, uterine leiomyomata, uterine anomalies, hypertensive disorders of pregnancy, and smoking.
The condition is increased in incidence by the presence of scar tissue i.e. Asherman's syndrome usually from past uterine surgery, especially from a past dilation and curettage, (which is used for many indications including miscarriage, termination, and postpartum hemorrhaging), myomectomy, or caesarean section. A thin decidua can also be a contributing factor to such trophoblastic invasion. Some studies suggest that the rate of incidence is higher when the fetus is female. Other risk factors include low-lying placenta, anterior placenta, congenital or acquired uterine defects (such as uterine septa), leiomyoma, ectopic implantation of placenta (including cornual pregnancy).
People above 35 years of age who have had a Caesarian section and now have a placenta previa overlying the uterine scar have 40% chance of placenta accreta.
The placenta forms an abnormally firm attachment to the uterine wall. There is absence of the decidua basalis and incomplete development of the Nitabuch's layer. There are three forms of placenta accreta, distinguishable by the depth of penetration.
|Placenta accreta||75–78%||The placenta attaches strongly to the myometrium, but does not penetrate it. This form of the condition accounts for around 75% of all cases.|
|Placenta increta||17%||Occurs when the placenta penetrates the myometrium.|
When the antepartum diagnosis of placenta accreta is made, it is usually based on ultrasound findings in the second or third trimester. Sonographic findings that may be suggestive of placenta accreta include:
- Loss of normal hypoechoic retroplacental zone
- Multiple vascular lacunae (irregular vascular spaces) within placenta, giving "Swiss cheese" appearance
- Blood vessels or placental tissue bridging uterine-placental margin, myometrial-bladder interface, or crossing uterine serosa1
- Retroplacental myometrial thickness of <1 mm
- Numerous coherent vessels visualized with 3-dimensional power Doppler in basal view
Although there are isolated case reports of placenta accreta being diagnosed in the first trimester or at the time of abortion <20 weeks' gestational age, the predictive value of first-trimester ultrasound for this diagnosis remains unknown. Women with a placenta previa or "low-lying placenta" overlying a uterine scar early in pregnancy should undergo follow-up imaging in the third trimester with attention to the potential presence of placenta accreta.
While obstetric ultrasound is the primary tool for the diagnosis of placenta accreta, magnetic resonance imaging can be helpful if ultrasound is inconclusive or if placenta percreta is suspected.
Examples include: (i) damage to local organs (e.g., bowel, bladder, ureters) and neurovascular structures in the retroperitoneum and lateral pelvic sidewalls from placental implantation and its removal; (ii) postoperative bleeding requiring repeated surgery; (iii) amniotic fluid embolism; (iv) complications (e.g., dilutional coagulopathy, consumptive coagulopathy, acute transfusion reactions, transfusion-associated lung injury, acute respiratory distress syndrome, and electrolyte abnormalities) from transfusion of large volumes of blood products, crystalloid, and other volume expanders; and (v) postoperative thromboembolism, infection, multisystem organ failure, and maternal death. The exact incidence of maternal mortality related to placenta accreta and its complications is unknown, but has been reported to be as high as 6-7% in case series and surveys.
The safest and most common treatment is a planned caesarean section and abdominal hysterectomy if placenta accreta is diagnosed before birth. Pitocin and antibiotics are used for post-surgical management. When there is partially separated placenta with focal accreta, best option is removal of placenta and oversewing the uterine defect. If it is important to save the woman's uterus (for future pregnancies) then resection around the placenta may be successful. Conservative treatment can also be uterus sparing but may not be as successful and has a higher risk of complications. Techniques include:
- Leaving the placenta in the uterus and curettage of uterus. Methotrexate has been used in this case, but there is no consensus whether this therapy is any more effective than observation.
- Intrauterine balloon catheterisation to compress blood vessels
- Embolisation of pelvic vessels
- Internal iliac artery ligation
- Bilateral uterine artery ligation
In cases where there is invasion of bladder, it is treated in similar manner to abdominal pregnancy and manual placental removal is avoided. However, this may eventually need hysterectomy and/or partial cystectomy.
If the patient decides to proceed with a vaginal delivery, blood products for transfusion and an anesthesiologist are kept ready at delivery.
The reported incidence of placenta accreta has increased from approximately 0.8 per 1000 deliveries in the 1980s to 3 per 1000 deliveries in the past decade.
Incidence has been increasing with increased rates of Caesarean deliveries, with rates of 1 in 4,027 pregnancies in the 1970s, 1 in 2,510 in the 1980s, and 1 in 533 for 1982–2002. In 2002, ACOG estimated that incidence has increased 10-fold over the past 50 years. The risk of placenta accreta in future deliveries after Caesarian section is 0.4-0.8%. For patients with placenta previa, risk increases with number of previous Caesarean sections, with rates of 3%, 11%, 40%, 61%, and 67% for the first, second, third, fourth, and fifth or greater number of Caesarean sections.
- Capella-Allouc, S.; Morsad, F; Rongières-Bertrand, C; Taylor, S; Fernandez, H (1999). "Hysteroscopic treatment of severe Asherman's syndrome and subsequent fertility". Human Reproduction. 14 (5): 1230–3. doi:10.1093/humrep/14.5.1230. PMID 10325268.
- Al-Serehi, A; Mhoyan, A; Brown, M; Benirschke, K; Hull, A; Pretorius, DH (2008). "Placenta accreta: An association with fibroids and Asherman syndrome". Journal of ultrasound in medicine. 27 (11): 1623–8. PMID 18946102.
- American Pregnancy Association (January 2004) 'Placenta Accreta'. Accessed 16 October 2006
- Arulkumaran, edited by Richard Warren, Sabaratnam (2009). Best practice in labour and delivery (1st ed., 3rd printing. ed.). Cambridge: Cambridge University Press. pp. 108, 146. ISBN 978-0-521-72068-7.
- Bass, KE; Morrish, D; Roth, I; Bhardwaj, D; Taylor, R; Zhou, Y; Fisher, SJ (August 1994). "Human cytotrophoblast invasion is up-regulated by epidermal growth factor: evidence that paracrine factors modify this process.". Developmental Biology. 164 (2): 550–61. doi:10.1006/dbio.1994.1223. PMID 8045351.
- Shimonovitz, S; Hurwitz, A; Dushnik, M; Anteby, E; Geva-Eldar, T; Yagel, S (September 1994). "Developmental regulation of the expression of 72 and 92 kd type IV collagenases in human trophoblasts: a possible mechanism for control of trophoblast invasion.". American Journal of Obstetrics and Gynecology. 171 (3): 832–8. doi:10.1016/0002-9378(94)90107-4. PMID 7522400.
- ACOG Committee on Obstetric, Practice (January 2002). "ACOG Committee opinion. Number 266, January 2002 : placenta accreta.". Obstetrics and gynecology. 99 (1): 169–70. doi:10.1016/s0029-7844(01)01748-3. PMID 11777527.
- Hobbins, John C. (2007). Obstetric ultrasound : artistry in practice. Oxford: Blackwell. p. 10. ISBN 978-1-4051-5815-2.
- Steven G. Gabbe; Jennifer R. Niebyl; Joe Leigh Simpson, eds. (2002). Obstetrics: normal and problem pregnancies (4. ed.). New York, NY [u.a.]: Churchill Livingstone. p. 519. ISBN 9780443065729.
- Johnston, T A; Paterson-Brown, S (January 2011). Placenta Praevia, Placenta Praevia Accreta and Vasa Praevia: Diagnosis and Management. Green-top Guideline No. 27. Royal College of Obstetricians and Gynecologists.
- Oyelese, Yinka; Smulian, John C. (2006). "Placenta Previa, Placenta Accreta, and Vasa Previa". Obstetrics & Gynecology. 107 (4): 927–41. doi:10.1097/01.AOG.0000207559.15715.98. PMID 16582134.
- Turrentine, John E. (2008). Clinical protocols in obstetrics and gynecology (3rd ed.). London: Informa Healthcare. p. 286. ISBN 9780415439961.
- Committee On Obstetric, Practice (2002). "Placenta accreta Number 266, January 2002 Committee on Obstetric Practice". International Journal of Gynecology & Obstetrics. 77 (1): 77–8. doi:10.1016/S0020-7292(02)80003-0. PMID 12053897.
- Committee on Obstetric Practice. "Placenta Accreta". American College of Obstetricians and Gynecologists.
- Silver, R.M.; Landon, M.B.; Rouse, D.J.; Leveno, K.J.; Spong, C.Y.; Thom, E.A.; Moawad, A.H.; Caritis, S. N.; Harper, M; Wapner, R. J.; Sorokin, Y; Miodovnik, M; Carpenter, M; Peaceman, A. M.; O'Sullivan, M. J.; Sibai, B; Langer, O; Thorp, J. M.; Ramin, S. M.; Mercer, B. M.; National Institute of Child Health Human Development Maternal-Fetal Medicine Units Network; et al. (2006). "Maternal morbidity associated with multiple repeat cesarean deliveries". Obstet Gynecol. 107 (6): 1226–32. doi:10.1097/01.AOG.0000219750.79480.84. PMID 16738145.